OS Therapies reports OST-HER2 delivering a meaningful survival signal in metastatic osteosarcoma, with 2-year OS at 75% vs 60% (p=0.034). Three-year OS data, key for conditional approvals, is slated for early Q4 2026, with EMA/TGA alignment and multiple regulatory meetings including a US FDA Type B discussion. If the data meet expectations, OSTX could advance an accelerated approval pathway in major markets, providing a near-term catalyst for the stock.
OS Therapies (OSTX) expects to submit conditional Marketing Authorization Applications to both the U.K.'s MHRA and the EMA by the end of Q1 2026. This milestone could enhance OSTX's competitive positioning and is critical for future revenue growth if approvals are granted.
OSTX shares are down significantly following positive biomarker data from its Phase 2b trial, which bolsters its upcoming Biologics License Application. Regulatory approval is targeted for early 2026 in key markets, yet current bearish momentum and recent stock performance raises concerns for investors.
